|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Actelion Pharmaceuticals US, Inc. (ATLN.VX) Selects Accredo Health Inc. (ACDO) to Distribute Epoprostenol for Injection for the Treatment of Moderate to Severe Pulmonary Arterial Hypertension
4/22/2010 10:40:28 AM
SOUTH SAN FRANCISCO, Calif. and MEMPHIS, Tenn., April 22 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., today announced that it has selected Accredo Health Group, Inc., a wholly-owned subsidiary of Medco Health Solutions, Inc., to serve as the sole specialty pharmacy provider of Epoprostenol for Injection, the only epoprostenol formulated to provide up to 24-hour stability at room temperature without the use of ice packs. This improved formulation of Epoprostenol for Injection is commercially available today in the United States for the treatment of primary pulmonary hypertension and pulmonary hypertension associated with scleroderma spectrum of disease in NYHA Class III and IV patients who do not respond adequately to conventional therapy.
|
|
|
|
|
|
|
|
|
|
|